CSL drug revenue faces 65 per cent cut by analysts
SYDNEY: Healthcare giant CSL’s shares are down 0.6 per cent to $114.68 in ...
To read the full story...SUBSCRIBE NOWExisting Subscribers Login Below:
Log In
